MB closer to IVF product launch with $12.5m series B
This article was originally published in Clinica
Molecular Biometrics (MB) is stepping up efforts for the global launch of ViaMetrics-E, its lead product for enhancing in vitro fertilisation outcomes, after raising $12.5m in series B financing. The round was led by new investor Atlas Venture, with contributions from existing shareholders Safeguard Scientifics and Oxford Bioscience Partners. The funds will enable the company to expand its commercial operations for the product launch outside the US, implement manufacturing and product enhancements and complete its ongoing FDA clinical study. ViaMetrics-E uses metabolomics, a complex scientific process, to identify viable embryos having the greatest reproductive potential, thereby improving pregnancy rates in IVF while reducing the risks of multiple births, says Norwood, Massachusetts-based MB.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.